PER
Click for more information
4.94% 8.5¢ percheron therapeutics limited

Ann: MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK, page-25

  1. itsagas
    13,075 Posts.
    lightbulb Created with Sketch. 1363
    clock Created with Sketch.
    28/06/23
    07:53
    Post #: 68503434
    the Sarepta chart shows that investors are disappointed that the FDA only gave Sareptas drug 901 partial approval
    Also in the first 1/4 2024 Sarepta has to prove efficacy on 901 …

    Let’s hope Gil Price can inform the PPMD https://hotcopper.com.au/data/attachments/5384/5384664-07864caa15215d28b81d094b60a9f353.jpgaudience that ANP iOS a serious contender for the DMD crown.




    Last edited by itsagas: 28/06/23
    ANP Price at posting: 6.4¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 4  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Microcap Wrap: 5 explorers with news out today
right-arrow Created with Sketch.
SFX Sheffield Resources achieves milestone production, shipments at Thunderbird, WA
right-arrow Created with Sketch.
PDN Paladin flags up to 4.5Mlbs of uranium production in FY25 guidance
right-arrow Created with Sketch.
PH2 Pure Hydrogen to supply hydrogen-fuelled garbage truck to City of Newcastle
right-arrow Created with Sketch.
RMS Ramelius boosts WA gold portfolio with stake in Spartan
right-arrow Created with Sketch.
LYC Lynas eyes first dysprosium, terbium HREE production in CY25
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.5¢ 		Change
0.004(4.94%) 		Mkt cap ! $76.63M
Open High Low Value Volume
8.1¢ 8.5¢ 8.1¢ $46.54K 563.7K

Buyers (Bids)

No. Vol. Price($)
2 164616 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.5¢ 100110 1
View Market Depth
Last trade - 15.55pm 28/06/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.